Press Releases


Press Releases

Date Title and Summary
Toggle Summary Foamix Pharmaceuticals to Present at the Barclays Global Healthcare Conference 2019
REHOVOT, Israel and BRIDGEWATER, N.J. , March 08, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology,
Toggle Summary Foamix Announces FDA Acceptance of New Drug Application for FMX101 Minocycline Foam for the Treatment of Moderate-to-Severe Acne
PDUFA Target Action Date of October 20th, 2019 REHOVOT, Israel , and BRIDGEWATER, N.J. , March 07, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to
Toggle Summary Foamix Pharmaceuticals to Present at the Cowen & Company 39th Annual Health Care Conference
REHOVOT, Israel and BRIDGEWATER, N.J. , March 06, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology,
Toggle Summary Foamix Reports Fiscal Year 2018 Financial Results and Provides Corporate Update
Conference Call Scheduled for Friday, March 1 at 8:30am Eastern Time REHOVOT, Israel and BRIDGEWATER, N.J. , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix Pharmaceuticals” or the “Company”), a clinical stage specialty pharmaceutical company focused on
Toggle Summary Foamix Announces Positive Results from Phase 3 Open-Label Safety Study Evaluating FMX103 Topical Minocycline Foam for Treatment up to 1 Year
Long Term Data on FMX103 Demonstrated a Generally Favorable Safety Profile; 81.6% of Patients Achieved Clear or Almost Clear Skin at 52 Weeks REHOVOT, Israel and BRIDGEWATER, N.J. , Feb. 27, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix” or the “Company”), a clinical
Toggle Summary Foamix -- with Late-Stage Candidates in Acne and Rosacea -- to Participate at American Academy of Dermatology Annual Meeting
REHOVOT, Israel and BRIDGEWATER, N.J. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in
Toggle Summary Foamix Pharmaceuticals Fourth Quarter Financial Results Conference Call & Webcast Scheduled for March 1
REHOVOT, Israel , and BRIDGEWATER, N.J. , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Appointment of Sharon Barbari to Board of Directors
REHOVOT, Israel , and BRIDGEWATER, N.J. , Jan. 23, 2019 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the
Toggle Summary Foamix Submits New Drug Application to U.S. FDA Seeking Approval of FMX101 in Treatment of Moderate-to-Severe Acne
REHOVOT, Israel and BRIDGEWATER, N.J. , Dec. 21, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that
Toggle Summary Foamix Announces Appointment of Matt Wiley as Chief Commercial Officer
REHOVOT, Israel , and BRIDGEWATER, N.J. , Nov. 27, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the
Toggle Summary Foamix Announces Appointment of Anthony Bruno to Board of Directors
REHOVOT, Israel and BRIDGEWATER, N.J. , Nov. 19, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced the
Toggle Summary Foamix Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Conference Call and Webcast Thursday, November 8, @ 8.30 am Eastern Time REHOVOT, Israel , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX) (“Foamix” or the “Company”), a clinical stage specialty pharmaceutical company focused on developing and commercializing
Toggle Summary Foamix Announces Positive Topline Results from Phase 3 Program Evaluating FMX103 Topical Minocycline Foam for Moderate-to-Severe Papulopustular Rosacea
FMX103 Demonstrated Highly Statistically Significant Improvement Compared with Vehicle in Both Co-Primary Efficacy Endpoints Conference Call and Webcast Today at 8:30 a.m. ET REHOVOT, Israel and BRIDGEWATER, N.J. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd.
Toggle Summary Foamix Pharmaceuticals Third Quarter Financial Results Conference Call & Webcast Scheduled for November 8
REHOVOT, Israel , and BRIDGEWATER, N.J. , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today
Toggle Summary Foamix to Present Clinical Data From Study FX2017-22 at the Fall Clinical Dermatology Conference
REHOVOT, Israel and BRIDGEWATER, N.J. , Oct. 12, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (NASDAQ: FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Additional Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne
Statistically significant improvement demonstrated in reduction of non-inflammatory lesions Dermal tolerability scores consistent with previous Phase 3 studies Re-analysis including patients from discontinued investigator site consistent with primary ITT analysis for both co-primary endpoints,
Toggle Summary Foamix Pharmaceuticals to Participate in the Cantor Fitzgerald Global Healthcare Conference
REHOVOT, Israel and BRIDGEWATER, N.J. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary, topical therapies to address unmet needs in dermatology, announced today
Toggle Summary Foamix Announces Closing of its Follow-on Offering of Ordinary Shares and Full Exercise of its Option by the Underwriters
REHOVOT, Israel , and BRIDGEWATER, N.J. , Sept. 18, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (“Foamix”) (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary, topical therapies to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Pricing of its Follow-on Offering of Ordinary Shares
REHOVOT, Israel and BRIDGEWATER, N.J. , Sept. 13, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (“Foamix”) (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary, topical therapies to address unmet needs in dermatology, today
Toggle Summary Foamix Announces Proposed Follow-on Offering of Ordinary Shares
REHOVOT, Israel , and BRIDGEWATER, N.J. , Sept. 12, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (“Foamix”) (Nasdaq: FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today